On the problem of neuropathic pain component diagnosis in patients with cancer pain syndrome

Cover Page

Cite item

Full Text

Abstract

Neuropathic pain component occurs in every second patient with pain syndrome caused by a malignant tumor. Detection of the neuropathic component of pain syndrome is crucial for selection of effective analgesia.

The review presents an application algorithm for an updated system of neuropathic pain component assessment in oncological patients.

About the authors

A. P. Spasova

Petrozavodsk State University

Author for correspondence.
Email: arina22@mail.ru
ORCID iD: 0000-0002-2797-4740

Arina Pavlovna Spasova

33 Lenina Prospekt, Petrozavodsk 185910

Russian Federation

A. M. Dorozhenko

V.A. Baranov Republican Hospital

ORCID iD: 0000-0002-0059-326X

3 Pirogova St., Petrozavodsk 185019

Russian Federation

A. A. Ryazankina

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7195-6307

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

O. Yu. Barysheva

Petrozavodsk State University

ORCID iD: 0000-0001-6317-1243

33 Lenina Prospekt, Petrozavodsk 185910

Russian Federation

A. N. Burganova

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0009-0001-9374-6498

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Russian Federation

E. V. Goncharova

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-4789-7460

6–8 L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

References

  1. Bennett M.I., Kaasa S., Barke A. et al. The IASP classification of chronic pain for ICD-11: chronic cancer-related pain. Pain 2019;160(1):38–44. doi: 10.1097/j.pain.0000000000001363
  2. Van den Beuken-van Everdingen M.H., Hochstenbach L.M., Joosten E.A. et al. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom manage 2016;51(6):1070–90. doi: 10.1016/j.jpainsymman.2015.12.340
  3. Haenen V., Dams L., Meeus M., De Groef A. Altered somatosensory functioning and mechanism-based classification in breast cancer patients with persistent pain. Anat Rec (Hoboken) 2024;307(2):273–84. doi: 10.1002/ar.25121
  4. Nijs J., Leysen L., Adriaenssens N. et al. Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta Oncol 2016;55(6):659–63. doi: 10.3109/0284186X.2016.1167958
  5. Oldenmenger W.H., Geerling J.I., Mostovaya I. et al. A systematic review of the effectiveness of patient-based educational interventions to improve cancer-related pain. Cancer Treat Rev 2017;63:96–103. doi: 10.1016/j.ctrv.2017.12.005
  6. Haroun R., Wood J.N., Sikandar S. Mechanisms of cancer pain. Front Pain Res (Lausanne) 2023;3:1030899. doi: 10.3389/fpain.2022.1030899
  7. Roberto A., Deandrea S., Greco M.T. et al. Prevalence of neuropathic pain in cancer patients: pooled estimates from a systematic review of published literature and results from a survey conducted in 50 Italian palliative care centers. J Pain Symptom manage 2016;51(6):1091–2.e4. doi: 10.1016/j.jpainsymman.2015.12.336
  8. Ilhan E., Chee E., Hush J., Moloney N. The prevalence of neuropathic pain is high after treatment for breast cancer: a systematic review. Pain 2017;158(11):2082–91. doi: 10.1097/j.pain.0000000000001004
  9. De Clauser L., Luiz A.P., Santana-Varela S. et al. Sensitization of cutaneous primary afferents in bone cancer revealed by in vivo calcium imaging. Cancers (Basel) 2020;12(12):3491. doi: 10.3390/cancers12123491
  10. Donnelly C.R., Andriessen A.S., Chen G. et al. Central nervous system targets: glial cell mechanisms in chronic pain. Neurotherapeutics 2020;17(3):846–60. doi: 10.1007/s13311-020-00905-7
  11. Duitama M., Moreno Y., Santander S.P. et al. TRP channels as molecular targets to relieve cancer pain. Biomolecules 2021;12(1):1. doi: 10.3390/biom12010001
  12. Kanat O., Ertas H., Caner B. Platinum-induced neurotoxicity: a review of possible mechanisms. World J Clin Oncol 2017;8(4):329–35. doi: 10.5306/wjco.v8.i4.329
  13. Kumar S.P. Cancer pain: a critical review of mechanism-based classification and physical therapy management in palliative care. Indian J Palliat Care 2011;17(2):116–26. doi: 10.4103/0973-1075.84532
  14. Merskey H., Bogduk N. Part III: Pain terms, a current list with definitions and notes on usage. In: Classification of chronic pain. 2nd ed. IASP Press. Pp. 209–14.
  15. Kosek E., Cohen M., Baron R. et al. Do we need a third mechanistic descriptor for chronic pain states? Pain 2016;157(7):1382–86. doi: 10.1097/j.pain.0000000000000507
  16. Kukushkin M.L., Yakhno N.N., Churyukanov M.V. et al. Nociplastic pain – new descriptor or simplified view on the problem? Rossiyskiy zhurnal boli = Russian Journal of Pain 2018;56(2):269–70. (In Russ.).
  17. Fitzcharles M.A., Cohen S.P., Clauw D.J. et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet 2021;397(10289):2098–110. doi: 10.1016/S0140-6736(21)00392-5
  18. Kosek E., Clauw D., Nijs J. et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain 2021;162(11):2629–34. doi: 10.1097/j.pain.0000000000002324
  19. Scarborough B. M., Smith C.B. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 2018;68(3):182–96. doi: 10.3322/caac.21453
  20. Leysen L., Adriaenssens N., Nijs J. et al. Chronic pain in breast cancer survivors: nociceptive, neuropathic, or central sensitization pain? Pain Pract 2019;19(2):183–95. doi: 10.1111/papr.12732
  21. Bennett M.I., Rayment C., Hjermstad M. et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 2012;153(2):359–65. doi: 10.1016/j.pain.2011.10.028
  22. Garzón-Rodríguez C., Lyras L., Gayoso L.O. et al. Cancer-related neuropathic pain in out-patient oncology clinics: a European survey. BmC Palliat Care 2013;12(1):41. doi: 10.1186/1472-684X-12-41
  23. Haanpää M., Attal N., Backonja m. et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152(1):14–27. doi: 10.1016/j.pain.2010.07.031
  24. Finnerup N.B., Haroutounian S., Kamerman P. et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016;157(8):1599–606. doi: 10.1097/j.pain.0000000000000492
  25. Edwards H.L., M ulvey m.R., Bennett M.I. Cancer-related neuropathic pain. Cancers (Basel) 2019;11(3):373. doi: 10.3390/cancers11030373
  26. Coffeen U., Sotomayor-Sobrino M.A., Jiménez-González A. et al. Chemotherapy-induced neuropathic pain characteristics in mexico’s National Cancer Center pain clinic. J Pain Res 2019;12:1331–9. doi: 10.2147/JPR.S186107
  27. Chen A. M., Hall W.H., Li J. et al. Brachial plexus-associated neuropathy after high-dose radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2012;84(1):165–9. doi: 10.1016/j.ijrobp.2011.11.019
  28. Mulvey M.R., Boland E.G., Bouhassira D. et al. Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles. Br J Anaesth 2017;119(4):765–74. doi: 10.1093/bja/aex175
  29. Wang M., Cheng H.L., Lopez V. et al. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BmC Cancer 2019;19(1):1151. doi: 10.1186/s12885-019-6352-3
  30. Pereira S., Fontes F., Sonin T. et al. Neurological complications of breast cancer: a prospective cohort study. Breast 2015;24(5):582–7. doi: 10.1016/j.breast.2015.05.006
  31. Høimyr H., Rokkones K.A., von Sperling M.L. et al. Persistent pain after lymph node excision in patients with malignant melanoma is neuropathic. Pain 2011;152(12):2721–8. doi: 10.1016/j.pain.2011.07.009
  32. Chen A. M., Wang P.C., Daly M.E. et al. Dose–volume modeling of brachial plexus-associated neuropathy after radiation therapy for head-and-neck cancer: findings from a prospective screening protocol. Int J Radiat Oncol Biol Phys 2014;88(4):771–7. doi: 10.1016/j.ijrobp.2013.11.244
  33. Boland E.G., Mulvey M.R., Bennett M.I. Classification of neuropathic pain in cancer patients. Curr Opin Support Palliat Care 2015;9(2):112–5. doi: 10.1097/SPC.0000000000000136
  34. Baron R., Binder A., Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9(8):807–19. doi: 10.1016/S1474-4422(10)70143-5
  35. Esin E., Yalcin S. Neuropathic cancer pain: what we are dealing with? How to manage it? Onco Targets Ther 2014;7:599–618. doi: 10.2147/OTT.S60995
  36. Andersen K.G., Duriaud H. M., Kehlet H., Aasvang E.K. The relationship between sensory loss and persistent pain 1 year after breast cancer surgery. J Pain 2017;18(9):1129–38. doi: 10.1016/j.jpain.2017.05.002
  37. Mustonen L., Vollert J., Rice A.S.C. et al. Sensory profiles in women with neuropathic pain after breast cancer surgery. Breast Cancer Res Treat 2020;182(2):305–15. doi: 10.1007/s10549-020-05681-8
  38. Vilholm O.J., Cold S., Rasmussen L., Sindrup S.H. Sensory function and pain in a population of patients treated for breast cancer. Acta Anaesthesiol Scand 2009;53(6):800–6. doi: 10.1111/j.1399-6576.2009.01938.x
  39. Martland M.E., Rashidi A.S., Bennett m.I. et al. The use of quantitative sensory testing in cancer pain assessment: a systematic review [published correction appears in Eur J Pain 2021;25(1):272]. Eur J Pain 2020;24(4):669–84. doi: 10.1002/ejp.1520
  40. De Carvalho Barbosa M., Kosturakis A.K., Eng C. et al. A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res 2014;74(21):5955–62. doi: 10.1158/0008-5472.CAN-14-2060
  41. Brozou V., Vadalouca A., Zis P. Pain in platin-induced neuropathies: a systematic review and meta-analysis. Pain Ther 2018;7(1):105–19. doi: 10.1007/s40122-017-0092-3
  42. Matsuoka A., Mitsuma A., maeda O. et al. Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-ofcare nerve conduction device. Cancer Sci 2016;107(10):1453–7. doi: 10.1111/cas.13010
  43. Dalla Torre C., Zambello R., Cacciavillani m. et al. Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study. Neurology 2016;87(11):1161–6. doi: 10.1212/WNL.0000000000003093
  44. Hill A., Bergin P., Hanning F. et al. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BmC Cancer 2010;10:451. doi: 10.1186/1471-2407-10-451
  45. Leone C., Federico V., La Cesa S. et al. An observational study assessing peripheral neuropathy related to multiple myeloma. Neurol Sci 2016;37(7):1141–3. doi: 10.1007/s10072-016-2542-9
  46. Lauria G., Hsieh S.T., Johansson O. et al. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010;17(7):903–12, e44–9. doi: 10.1111/j.1468-1331.2010.03023.x
  47. Briani C., Campagnolo M., Lucchetta M. et al. Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. Eur J Neurol 2013;20(1):188–92. doi: 10.1111/j.1468-1331.2012.03852.x
  48. Chalasani P., Taljanovic M., Segar J. et al. Diffuse tensor imaging of lower extremities: a novel mR imaging technique for chemotherapy-induced peripheral neuropathy. Breast Cancer Res Treat 2020;184(3):771–8. doi: 10.1007/s10549-020-05897-8
  49. Apostolidis L., Schwarz D., Xia A. et al. Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy. PLoS One 2017;12(8):e0183845. doi: 10.1371/journal.pone.0183845
  50. Lycan T.W., Hsu F.C., Ahn C.S. et al. Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. muscle Nerve 2020;61(5):587–94. doi: 10.1002/mus.26833
  51. Truini A., Biasiotta A., Cesa S. et al. mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. Pain 2010;150(3):516–21. doi: 10.1016/j.pain.2010.06.006

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Spasova A.P., Dorozhenko A.M., Ryazankina A.A., Barysheva O.Y., Burganova A.N., Goncharova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-86325 от  11.12.2023.